About: Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development
Creator	Tsybovsky, Yaroslav Mascola, John Graham, Barney Mclellan, Jason Dormitzer, Philip Morabito, Kaitlyn Stewart-Jones, Guillaume Gbe, Stewart-Jones Kavanagh, Owen Hutchinson, Geoffrey Loomis, Rebecca Caringal, Ria Chamberlain, Amy Gb, Hutchinson Jansen, Kathrin Js, Mclellan Km, Morabito Kueltzo, Lisa La, Kueltzo Nugent, Sean Rj, Loomis Rt, Caringal St, Nugent
topic	covid:f6a9ebbd5857b3ca644f10b65686ccf1a68cbfeb#this
source	PMC
abstract	Licensed vaccines or therapeutics are rarely available for pathogens with epidemic or pandemic potential. Developing interventions for specific pathogens and defining generalizable approaches for related pathogens is a global priority and inherent to the UN Sustainable Development Goals. Nipah virus (NiV) poses a significant epidemic threat, and zoonotic transmission from bats-to-humans with high fatality rates occurs almost annually. Human-to-human transmission of NiV has been documented in recent outbreaks leading public health officials and government agencies to declare an urgent need for effective vaccines and therapeutics. Here, we evaluate NiV vaccine antigen design options including the fusion glycoprotein (F) and the major attachment glycoprotein (G). A stabilized prefusion F (pre-F), multimeric G constructs, and chimeric proteins containing both pre-F and G were developed as protein subunit candidate vaccines. The proteins were evaluated for antigenicity and structural integrity using kinetic binding assays, electron microscopy, and other biophysical properties. Immunogenicity of the vaccine antigens was evaluated in mice. The stabilized pre-F trimer and hexameric G immunogens both induced serum neutralizing activity in mice, while the post-F trimer immunogen did not elicit neutralizing activity. The pre-F trimer covalently linked to three G monomers (pre-F/G) induced potent neutralizing antibody activity, elicited responses to the greatest diversity of antigenic sites, and is the lead candidate for clinical development. The specific stabilizing mutations and immunogen designs utilized for NiV were successfully applied to other henipaviruses, supporting the concept of identifying generalizable solutions for prototype pathogens as an approach to pandemic preparedness.
has issue date	2020-06-11(xsd:dateTime)
bibo:doi	10.3389/fimmu.2020.00842
has license	cc-by
sha1sum (hex)	f6a9ebbd5857b3ca644f10b65686ccf1a68cbfeb
schema:url	https://doi.org/10.3389/fimmu.2020.00842
resource representing a document's title	Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development
has PubMed Central identifier	PMC7300195
schema:publication	Front Immunol
resource representing a document's body	covid:f6a9ebbd5857b3ca644f10b65686ccf1a68cbfeb#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/f6a9ebbd5857b3ca644f10b65686ccf1a68cbfeb
is schema:about of	named entity 'transfected' named entity 'hexameric' named entity '3.8' named entity 'NiV' named entity 'multimeric' named entity 'gel filtration' named entity 'Cedar virus' named entity 'protein' named entity 'fusion protein' named entity 'epitopes' named entity 'NiV' named entity 'supernatant' named entity 'infection' named entity 'Cedar virus' named entity 'kinetics' named entity 'protein' named entity 'VSV' named entity 'disulfide bonds' named entity 'trimer' named entity 'wild-type' named entity 'United States' named entity 'wild-type' named entity 'extracellular region' named entity 'Serum samples' named entity 'epitopes' named entity 'protein structure' named entity 'NiV' named entity 'luciferase' named entity 'immunogen' named entity 'subunit vaccine' named entity 'glycoproteins' named entity 'NiV' named entity 'coronaviruses' named entity 'microscope' named entity 'F/G' named entity 'protein expression' named entity 'C-terminal' named entity 'biophysical' named entity 'luciferase' named entity 'light chains' named entity 'CDC' named entity 'antigens' named entity 'postfusion' named entity 'C-terminal' named entity 'paramyxovirus' named entity 'titer' named entity 'non-linear regression' named entity 'antibody' named entity 'Patent Application' named entity 'paramyxoviruses' named entity 'viruses' named entity 'negative-stain' named entity 'light chain' named entity 'room temperature' named entity 'ectodomain' named entity 'proline' named entity 'multimeric' named entity 'lysis' named entity 'mutation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software